QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ghosal, A. Articles by Zbaida, S. Search for Related Content PubMed PubMed Citation Articles by Ghosal, A. Articles by Zbaida, S.

IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF POSACONAZOLE (NOXAFIL)

Drug Metabolism and Pharmacokinetics, Schering-Plough Research Institute, Kenilworth, New Jersey

(Received August 20, 2003; accepted October 10, 2003)

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Posaconazole (Noxafil, SCH 56592), an orally available broad-spectrum triazole antifungal, is currently in phase III clinical studies for treating serious opportunistic fungal infections. The major in vitro metabolite of posaconazole formed by human liver microsomes supplemented with uridine 5'-diphosphate-glucuronic acid was a glucuronide of posaconazole (m/z877). Screening of 10 cDNA-expressed recombinant human UDP-glucuronosyltransferase (UGT) enzymes showed that only UGT1A4 exhibited catalytic activity with respect to the formation of the glucuronide of posaconazole. The formation of glucuronide by human liver microsomes and UGT1A4 was inhibited by bilirubin, a known inhibitor of UGT1A4. There was a high correlation (r =0.90) between the rate of formation of glucuronide, determined in 10 human liver microsomal samples, and trifluoperazine glucuronidation catalyzed by UGT1A4. These results confirmed that the formation of major posaconazole-glucuronide produced from human liver microsomes was mediated via UGT1A4.

Posaconazole is a triazole derivative that is being developed as an antifungal agent (Barchiesi et al., 2001; Pfaller et al., 2001; Gonzalez et al., 2002). As with all azole antifungal agents, posaconazole works principally by inhibition of cytochrome P450 14-demethylase (P45014DM). This enzyme is in the sterol biosynthesis pathway that leads from lanosterol to ergosterol. Compared with itraconazole, posaconazole is a significantly more potent inhibitor of sterol C14 demethylation, particularly in Aspergillus. Preliminary data showed that posaconazole and several glucuronide conjugates of posaconazole were present in human plasma and urine (P. Krieter, B. Flannery, T. Musick, M. Gohdes, M. Martinho, and R. Courtney, manuscript submitted for publication). The objective of this study was to identify the predominant in vitro UGT-conjugation pathway(s) for posaconazole.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Chemicals. UDP-glucuronic acid, Glucurase, magnesium chloride, Trizma base, saccharolactone (D-saccharic acid 1,4-lactone), alamethicin, trifluoperazine, bilirubin, and 4-trifluoromethyl-7-hydroxycoumarin glucuronide (4-trifluoromethylumbelliferyl glucuronide) were purchased from Sigma-Aldrich (St. Louis, MO). 7-Hydroxy-4-trifluoromethylcoumarin (7-HFC) was obtained from BD Gentest (Woburn, MA). Acetonitrile (HPLC grade) was obtained from Burdick & Jackson (Muskegon, MI). Dimethyl sulfoxide and methanol were obtained from Fisher Scientific (Pittsburgh, PA). Unlabeled and radiolabeled posaconazole (¹⁴C-SCH 56592, specific activity 80.3 µCi/mg, radiochemical purity 98.6%; Fig. 1) were prepared at Schering-Plough Research Institute (Kenilworth, NJ). Pooled human liver microsomes (n = 10) were purchased from XenoTech, LLC (Kansas City, KS). UGT Supersomes (human UGT enzymes developed using baculovirus-insect cell-expression system) were purchased from BD Gentest and Baculosomes (UGT1A7 and UGT1A10) were obtained from PanVera (Madison, WI).

View larger version (9K): [in this window] [in a new window]   FIG. 1. Chemical structure of posaconazole (SCH 56592). * denotes site of 14C label

Analysis of Posaconazole and Glucuronide(s). The analysis was performed on a Waters Alliance HPLC system (Alliance model 2690; Waters Corporation, Milford, MA), equipped with a model 996 Photodiode Array Detector (Waters Corporation), a model 500TR Radioactivity Detector (PerkinElmer Life and Analytical Sciences, Boston, MA), and a 5-µm Zorbax RX-C8 250 x 4.6 mm column (Mac-Mod Analytical Inc., Chadds Ford, PA). The analytical column was maintained at room temperature for all HPLC experiments. The mobile phase, consisting of water (A) and methanol (B), was operated at a constant flow rate (1 ml/min), and the metabolite was detected at 260 nm. The gradient was 10% B for 0.1 min, followed by a rapid increase to 100% B in 46 min, 5 min at 100%, and a re-equilibrium at 10% B. After LC analysis, the concentrations of glucuronides were calculated based on radiometric detection and a standard curve (linear) of five points. All LC/MS and LC/tandem MS experiments were performed by using a TSQ 7000 mass spectrometer (Thermo Finnigan, San Jose, CA).

Enzyme Assays. Incubation of posaconazole with pooled human liver microsomes. Substrate concentrations of 0.5 to 50 µM, microsomal protein concentrations of 0.05 to 2 mg/ml, and incubation times of 15 to 240 min were used to optimize the condition of the assay. Instead of treating with detergent, the microsomes were treated with alamethicin (a 20-amino acid -helical pore-forming peptide) at 50 µg of alamethicin/mg of microsomal protein on ice for 15 min to diminish the latency of UGT activity (Fisher et al., 2000). All microsomal incubations contained microsomes treated with alamethicin, 10 mM magnesium chloride, 5 mM saccharolactone (an inhibitor of ß-glucuronidase), and ¹⁴C-posaconazole in 0.5 ml of 0.1 M Tris-HCl buffer, pH 7.4 (Pless et al., 1999). Before the addition of UDPGA, the incubation mixtures were prewarmed for 3 min at 37°C. The reactions were initiated by the addition of 2 mM UDPGA, allowed to proceed for 120 min at 37°C, and terminated with ice-cold methanol. The incubation mixtures were vortexed and centrifuged (10,010g) at 4°C for 10 min, and the supernatants were analyzed by HPLC. Incubations without UDPGA and boiled human liver microsomes served as a negative control. For LC/MS analyses, the reactions were either terminated as described above or terminated by cooling in ice-water followed by solid phase extraction.

Determination of enzyme activities of UGT Supersomes and microsomes. The activities of UGT Supersomes (UGT1A1, UGT1A3, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15) and human liver microsomes were determined in assays using HPLC and 7-HFC as substrate according to the UGT Batch Data Sheet provided by BD Gentest. The assay was performed with 1 mg/ml UGT Supersomes or microsomes treated with alamethicin (50 µg/ml), 10 mM magnesium chloride, 5 mM saccharolactone, and 50 µM 7-HFC in 0.1 M Tris-HCl buffer, pH 7.4. Before the addition of UDPGA, the incubation mixture was prewarmed for 3 min at 37°C. The reactions were initiated by the addition of 2 mM UDPGA and incubated for 20 min at 37°C; the reactions were terminated with 250 µl of ice-cold methanol. The incubation mixture was vortexed and centrifuged (10,010g) at 4°C for 10 min, and the supernatants were analyzed by HPLC. The formation of glucuronide was quantitated by comparing to the absorbance of a standard curve for 4-trifluoromethyl-7-hydroxycoumarin glucuronide.

Determination of enzyme activity of UGT1A4 Supersomes using trifluoperazine. UGT1A4 Supersomes do not form glucuronides with 7-HFC as a substrate. Therefore, the activity of UGT1A4 Supersomes was determined in assays using HPLC and trifluoperazine substrate as described by Dehal et al. (2001) with modifications. The assay was performed with 0.5 mg/ml UGT1A4 and 200 µM trifluoperazine substrate in 0.1 M Tris-HCl buffer, pH 7.4. The reactions were initiated by the addition of 2 mM UDPGA and incubated for 20 min at 37°C; the reactions were terminated with 250 µl of ice-cold methanol. The incubation mixture was vortexed and centrifuged (10,010g) at 4°C for 10 min, and the supernatants were analyzed by HPLC (Dehal et al., 2001).

Screening of 10 human UGT Supersomes. In vitro screening of 10 human UGT Supersomes (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15) with posaconazole were performed using a constant amount of microsomal protein (1 mg/ml) and 5 and 30 µM SCH 56592. All incubations with Supersomes were carried out as described earlier. Insect cell microsomes without UGT cDNA served as the negative control. These samples were also analyzed by LC/MS.

Kinetic parameters (K_m and V_max) of posaconazole glucuronidation by UGT1A4 Supersomes was determined as described below. Substrate concentrations of 0.5 to 50 µM, UGT protein concentrations of 1 mg/ml, and incubation time of 60 min were used to incubate UGT1A4 to determine K_m and V_max. The incubation was performed as described above, and insect microsomes without UGT cDNA served as negative control.

Inhibition with chemical inhibitors of UGTs. Inhibition of posaconazole metabolism was evaluated using bilirubin, a known chemical inhibitor of UGT1A4. Human liver microsomes (1 mg/ml) or human UGT Supersomes (1 mg/ml) were preincubated with various concentrations of bilirubin in dimethyl sulfoxide for 15 min at room temperature followed by the addition of buffer, alamethicin, saccharolactone, cofactor, and substrate. The final concentration of the organic solvent in the incubation system was 1 to 3%, and all control incubations contained the same volume of appropriate vehicle. All organic solvents tested up to 3% (v/v) had no effect on the formation of glucuronides. All incubations were carried out as described before except that the concentration of ¹⁴C-posaconazole was 30 µM in the case of human liver microsomes and 20 µM in the case of UGT1A4. The reactions were initiated by the addition of 2 mM UDPGA, incubated for 120 min (human liver microsomes) or 60 min (UGT1A4) at 37°C, and terminated with cold methanol. The incubation mixture was vortexed and centrifuged (10,010g) at 4°C for 10 min; the supernatants were saved for further analyses by HPLC.

Correlation Study. Ten individual human liver microsomal preparations from 10 individual donors (includes data for UGT-specific enzyme activities) were obtained from BD Gentest. The ability of human liver microsomes from each donor to glucuronidate posaconazole was correlated with the UGT-specific enzyme activities for each sample. The assays were performed as described previously with 30 µM substrate and incubated for 120 min.

Analysis of Kinetic Data. Untransformed enzyme kinetic data were analyzed by a nonlinear regression data analysis program (GraFit 4.0; Erithacus Software Ltd., Horley, Surrey, UK), assuming Michaelis-Menten kinetics over the substrate range studied.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Optimization and Incubation with Pooled Human Liver Microsomes. After incubation of 30 µM ¹⁴C-posaconazole (Fig. 1) with pooled human liver microsomes and UDPGA, one major glucuronide was observed by radiometric detection (Fig. 2). As expected, incubation without UDPGA and with boiled microsomes did not yield any glucuronide (results not shown). LC/MS analysis of the extract following incubation of ¹⁴C-posaconazole with pooled human liver microsomes and UDPGA confirmed the presence of glucuronide (m/z 877). A posaconazole-glucuronide at this retention time was observed also in an in vivo study in healthy male subjects following oral administration of posaconazole (P. Krieter, B. Flannery, T. Musick, M. Gohdes, M. Martinho, and R. Courtney, manuscript submitted for publication). Four separate posaconazole-glucuronides were detected in plasma and urine (P. Krieter, B. Flannery, T. Musick, M. Gohdes, M. Martinho, and R. Courtney, manuscript submitted for publication). Based on NMR spectra and electronic calculations, this glucuronide was identified as N-glucuronide (P. Krieter, B. Flannery, T. Musick, M. Gohdes, M. Martinho, and R. Courtney, manuscript submitted for publication). However, the chemical structure of the other three glucuronides has not been identified.

View larger version (15K): [in this window] [in a new window]   FIG. 2. Radiometric profile of metabolites following 120-min incubation of 30 µM 14C-posaconazole (14C-SCH 56592) with active human liver microsomes (top panel) or recombinant UGT1A4 Supersomes (bottom panel) supplemented with UDPGA.

When pooled human liver microsomes were incubated using various protein concentrations (0.05-2 mg/ml) and for various time periods (15-240 min), 1 mg/ml protein and 120 min were found to be optimal based on the linearity and percentage of conversion to its glucuronide. The effect of various substrate concentrations (0.5-50 µM) on posaconazole-glucuronides demonstrated that the apparent K_m and V_max values for the glucuronide formation were 27.9 µM and 15.3 pmol/mg protein/min, respectively (Table 1; Fig. 3). The intrinsic clearance (V_max/K_m) value for the glucuronide was estimated to be 0.55. A substrate concentration of 30 µM was chosen for further experiments with human liver microsomes considering the linearity and sensitivity of detection. In the absence of the UDPGA or with boiled microsomes, no metabolite formation was observed.

View larger version (20K): [in this window] [in a new window]   FIG. 3. Enzyme kinetics for the formation of glucuronide conjugate of posaconazole (SCH 56592) incubated with pooled human liver microsomes (top panel) or UGT1A4 Supersomes (bottom panel).

Activities of Human UGT Supersomes and Human Liver Microsomes (Positive Control). The results of the activity determination of 10 human UGT Supersomes (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15) and human liver microsomes are presented in Table 2. These results served as positive control for the UGT activities and demonstrated that the Supersomes and microsomes were active. The data from these positive control experiments demonstrate that 7-HFC is a substrate for all UGTs studied except UGT1A4, whereas trifluoperazine is the substrate for only UGT1A4 (Table 2).

Screening with Human UGT Supersomes. Incubation of posaconazole (5 and 30 µM) with 10 human UGT Supersomes (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15) revealed that only UGT1A4 metabolized posaconazole to the major in vitro glucuronide (Fig. 4). No metabolism was observed with other UGTs and control insect microsomes. The metabolite profiles suggested that only UGT1A4 is primarily responsible for the in vitro glucuronidation of posaconazole (Fig. 2). The recovery of metabolites from the HPLC column was on average >96%.

View larger version (11K): [in this window] [in a new window]   FIG. 4. Screening of UGT Supersomes for the formation of glucuronide conjugate of posaconazole (SCH 56592) at 5 and 30 µM.

When UGT1A4 Supersomes were incubated using various protein concentrations (0.5-2 mg/ml) and for various time periods (15-120 min), 1 mg/ml protein and 60 min were found to be optimal based on the linearity and percentage of conversion to its glucuronide. Incubation of various concentrations of posaconazole (0.5-50 µM) with UGT1A4 Supersomes demonstrated that the apparent K_m and V_max values for posaconazole-glucuronide were 15.9 µM and 16.9 pmol/mg protein/min, respectively (Table 1; Fig. 3). Intrinsic clearance (V_max/K_m) for this glucuronide was estimated to be 1.06.

Inhibition Study. All inhibition studies were performed with pooled human liver microsomes at a drug concentration of 30 µM. UGT1A4 Supersomes were also incubated with inhibitors as positive control (20 µM posaconazole) to confirm the specificity of the inhibitors. The effect of incubations with UGT1A4-inhibitor and (bilirubin) is presented in Fig. 5 and Table 3. Bilirubin was shown to be a potent inhibitor of glucuronide formation by human liver microsomes (>79% inhibition). The IC₅₀ value was 11.1 µM (Fig. 5). Bilirubin was also an inhibitor of UGT1A4 Supersomes (Table 3). These results suggested that UGT1A4 might be involved in the formation of glucuronide in human liver microsomes.

View larger version (16K): [in this window] [in a new window]   FIG. 5. Inhibition curve of bilirubin (IC50) for the formation of glucuronide from posaconazole incubated with pooled human liver microsomes.

Correlation Studies. The rate of formation of ¹⁴C-posaconazole-glucuronide was measured in each of the 10 human liver microsomal samples obtained from BD Gentest and correlated with the biochemical activities data provided by the vendor. Since the biochemical activity data were mediated by specific UGT enzymes, high correlation would suggest that similar enzymes were involved in the formation of metabolites from posaconazole.

The highest correlation between the BD Gentest assay data (n = 10) and the formation of glucuronide was noted for trifluoperazine glucuronidation (r = 0.90) catalyzed by UGT1A4 at 30 µM posaconazole (Fig. 6). Trifluoperazine was reported as a substrate of UGT1A4 in the literature by Ghosheh and Hawes (2002) and Linnet (2002). There was no significant correlation between estradiol 3-glucuronidation (catalyzed by UGT1A1, r = 0.35) or propofol glucuronidation (catalyzed by UGT1A9, r = 0.38) and posaconazole-glucuronide formation (results not shown). The results of correlation analysis between the enzyme activities and metabolite formation suggested that posaconazole is glucuronidated exclusively by UGT1A4 in human liver microsomes.

View larger version (13K): [in this window] [in a new window]   FIG. 6. Correlation between formation of glucuronide from 30 µM posaconazole incubated separately with 10 individual human liver microsomes and trifluoperazine glucuronidation (UGT1A4 activity).

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
Incubation of posaconazole with human liver microsomes supplemented with UDPGA resulted in the formation of one major metabolite (Fig. 2). This metabolite (m/z 877) was identified by LC/MS as the glucuronide of posaconazole (SCH 56592). Formation of this posaconazole-glucuronide was mediated by UGT1A4, based on the metabolite profiles following incubation of posaconazole with cell microsomes overexpressing UGT1A4, high correlation with trifluoperazine glucuronidation, and inhibition by bilirubin (Table 3; Figs. 4, 5, 6).

In vitro incubation with 10 different recombinant human UGT Supersomes showed that only UGT1A4 exhibited activity for the formation of posaconazole-glucuronide (Fig. 4). Bilirubin is a known specific inhibitor of UGT1A1 in the literature. However, bilirubin was also reported as a substrate and inhibitor of UGT1A4 by Hiller et al., 1999. Since the results of inhibition studies with recombinant UGT1A4 Supersomes showed that bilirubin was an inhibitor of posaconazole-glucuronide formation from UGT1A4 (Table 3), it was used as a UGT1A4-inhibitor in this study. At 100 µM concentration, bilirubin inhibited formation of the glucuronide from human liver microsomes and UGT1A4 Supersomes by 79.6% and 63.5%, respectively. In addition, there was highly significant correlation between the formation of posaconazole-glucuronide and trifluoperazine glucuronidation known to be mediated by UGT1A4 (Fig. 6). These results confirmed the involvement of UGT1A4 in the formation of posaconazole-glucuronide.

	Footnotes

 
¹ Abbreviations used are: UGT, UDP-glucuronosyltransferase; UDPGA, uridine 5'-diphosphate-glucuronic acid; 7-HFC, 7-hydroxy-4-trifluoromethylcoumarin; HPLC, high-performance liquid chromatography; SCH 56592, posaconazole; LC/MS, liquid chromatography/mass spectrometry; saccharolactone,D-saccharic acid 1,4-lactone.

Address correspondence to: Dr. Anima Ghosal, Drug Metabolism and Pharmacokinetics, Schering-Plough Research Institute, 2015 Galloping Hill Road, K-15-1945, Kenilworth, NJ 07033. E-mail: anima.ghosal{at}spcorp.com

	References

Top Abstract Materials and Methods Results Discussion References

 


Barchiesi F, Schimizzi AM, Caselli F, Giannini D, Camiletti V, Fileni B, Giacometti A, Di Francesco LF, and Scalise G (2001) Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother 48: 769-773.[Abstract/Free Full Text]

Dehal SS, Gagne PV, Crespi CL, and Patten CJ (2001) Characterization of a probe substrate and an inhibitor of UDP glucuronosyltransferase (UGT) 1A4 activity in human liver microsomes (HLM) and cDNA-expressed UGT-enzymes. Abstract 321, in 6th International ISSX Meeting, Munich, Germany, p. 162.

Fisher MB, Campanale K, Ackermann BL, Vandenbranden M, and Wrighton SA (2000) In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28: 560-566.[Abstract/Free Full Text]

Ghosheh O and Hawes EM (2002) N-glucuronidation of nicotine and cotinine in human: formation of cotinine glucuronide in liver microsomes and lack of catalysis by 10 examined UDP-glucuronosyltransferases. Drug Metab Dispos 30: 991-996.[Abstract/Free Full Text]

Gonzalez GM, Tijerina R, Najvar LK, Bocanegra R, Rinaldi M, Loebenberg D, and Graybill JR (2002) In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob Agents Chemother 46: 1352-1356.[Abstract/Free Full Text]

Hiller A, Nguyen N, Strassburg CP, Li Q, Jainta H, Pechstein B, Ruus P, Engel J, Tukey RH, and Kronbach T (1999) Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos 27: 605-612.[Abstract/Free Full Text]

Linnet K (2002) Glucuronidation of olanzapine by cDNA-expressed human UDP glucuronosyl-transferases and human liver microsomes Hum Psychopharmacol 17: 233-238.[CrossRef][Medline]

Pfaller, MA, Messer SA, Hollis RJ, Jones RN, and The SENTRY Participants Group (2001) Antifungal activity of posaconazole, ravuconazole and voriconazole compared to that of itraconazole tested against 213 clinical isolates of Aspergillus spp. and other filamentous fungi: report from the SENTRY Antimicrobial Surveillance Program, 2000. Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL, p 379.

Pless D, Gouze JN, Senay C, Herber R, Leroy P, Barberousse V, Fournel-Gigleux S, and Magdalou J (1999) Characterization of the UDP-glucuronosyltransferases involved in the glucuronidation of an antithrombotic thioxyloside in rat and humans. Drug Metab Dispos 27: 588-595.[Abstract/Free Full Text]

Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, ex-pression and disease. Annu Rev Pharmacol Toxicol 40: 581-616.[CrossRef][Medline]

This article has been cited by other articles:

				K. Omura, T. Nakazawa, T. Sato, T. Iwanaga, and O. Nagata Characterization of N-Glucuronidation of 4-(5-Pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): A New Xanthine Oxidoreductase Inhibitor Drug Metab. Dispos., December 1, 2007; 35(12): 2143 - 2148. [Abstract] [Full Text] [PDF]

				R. Fujiwara, M. Nakajima, H. Yamanaka, A. Nakamura, M. Katoh, S.-i. Ikushiro, T. Sakaki, and T. Yokoi Effects of Coexpression of UGT1A9 on Enzymatic Activities of Human UGT1A Isoforms Drug Metab. Dispos., May 1, 2007; 35(5): 747 - 757. [Abstract] [Full Text] [PDF]

				Z. Wen, M. N. Tallman, S. Y. Ali, and P. C. Smith UDP-Glucuronosyltransferase 1A1 Is the Principal Enzyme Responsible for Etoposide Glucuronidation in Human Liver and Intestinal Microsomes: Structural Characterization of Phenolic and Alcoholic Glucuronides of Etoposide and Estimation of Enzyme Kinetics Drug Metab. Dispos., March 1, 2007; 35(3): 371 - 380. [Abstract] [Full Text] [PDF]

				A. Sansone-Parsons, G. Krishna, J. Simon, P. Soni, B. Kantesaria, J. Herron, and R. Stoltz Effects of Age, Gender, and Race/Ethnicity on the Pharmacokinetics of Posaconazole in Healthy Volunteers Antimicrob. Agents Chemother., February 1, 2007; 51(2): 495 - 502. [Abstract] [Full Text] [PDF]

				J. Meletiadis, S. Chanock, and T. J. Walsh Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy Clin. Microbiol. Rev., October 1, 2006; 19(4): 763 - 787. [Abstract] [Full Text] [PDF]

				V. Uchaipichat, P. I. Mackenzie, D. J. Elliot, and J. O. Miners SELECTIVITY OF SUBSTRATE (TRIFLUOPERAZINE) AND INHIBITOR (AMITRIPTYLINE, ANDROSTERONE, CANRENOIC ACID, HECOGENIN, PHENYLBUTAZONE, QUINIDINE, QUININE, AND SULFINPYRAZONE) "PROBES" FOR HUMAN UDP-GLUCURONOSYLTRANSFERASES Drug Metab. Dispos., March 1, 2006; 34(3): 449 - 456. [Abstract] [Full Text] [PDF]

				N. B. Sandson, S. C. Armstrong, and K. L. Cozza An Overview of Psychotropic Drug-Drug Interactions Psychosomatics, October 1, 2005; 46(5): 464 - 494. [Abstract] [Full Text] [PDF]

				A. Di Marco, M. D'Antoni, S. Attaccalite, P. Carotenuto, and R. Laufer DETERMINATION OF DRUG GLUCURONIDATION AND UDP-GLUCURONOSYLTRANSFERASE SELECTIVITY USING A 96-WELL RADIOMETRIC ASSAY Drug Metab. Dispos., June 1, 2005; 33(6): 812 - 819. [Abstract] [Full Text] [PDF]

				H. Kaji and T. Kume CHARACTERIZATION OF AFLOQUALONE N-GLUCURONIDATION: SPECIES DIFFERENCES AND IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ISOFORM(S) Drug Metab. Dispos., January 1, 2005; 33(1): 60 - 67. [Abstract] [Full Text] [PDF]

				P. Krieter, B. Flannery, T. Musick, M. Gohdes, M. Martinho, and R. Courtney Disposition of Posaconazole following Single-Dose Oral Administration in Healthy Subjects Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3543 - 3551. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ghosal, A. Articles by Zbaida, S. Search for Related Content PubMed PubMed Citation Articles by Ghosal, A. Articles by Zbaida, S.